Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well.. @RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ

#POS0709 #EULAR2022 Pooled analyses of TULIP-1 & -2 RCTs showed sustained & #lupus patients spent longer time in BICLA response vs Placebo up to 52 Wks. BILAG response was sustained in MSK, skin and constitutional domains. Be interesting to see longer follow-up data @RheumNow https://t.co/kNk7WFloLf

Watch: EULAR Recommendations for ANCA Vasculitis Dr. Eric Dein reviews the session held on updates to recommendations for ANCA Vasculitis, presented at the #EULAR2022 meeting in June. https://t.co/1nr0tVIJpn https://t.co/kq0Id7PxyW

• https://bit.ly/3Nb0xM5

A Big Leap in Modulating Rheumatoid Disease Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. https://t.co/QHK7c3Qhz6 https://t.co/jFR9wDCD8o

• https://bit.ly/3NajsX7

CTD associated ILD 🫁: lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc- ILD and RA-ILD vs. non ILD patients with AUC 0.79. As many lncRNA, unknown if biomarker only or has a pathogenic role. @RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD

Lung 🫁 cancer incidence and RA 44000+ RA (EIRA prospective cohort) and 216000+ matched Ctrls Swedish registries 📍56 per 100,000 📍HR 1.77 (adjusted for smoking 🚬) 📍Risk in RA + smoking 7x higher 📍Risk 2x in Sero+ vs. sero- No data on ttmt #EULAR2022 @RheumNow POS0061 https://t.co/c7eh3icW2c

B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬 FCGR3A-158V: *encodes the allotype ⬆️ affinity for IgG1 *is associated w/ clinical and biological responses in RA and SLE. A new way to stratify pts for anti-CD20 therapy? @Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71

Great meeting @RheumNow. He does a great job of educating Rheumatologists around the world especially through his podcast. Great discussion on the usefulness of ultrasound for Rheumatologists #EULAR2022 https://t.co/0hw7mpX8dm

Pascual et al. Anti-TIF1gamma and cancer risk in DM and non-DM. Cancer in 60% of DM and 21% of non-DM patients with Anti-TIF1gamma https://t.co/OxKdlmDBBD

Kristensen et al. 52 week results KEEPsAKE 1 RCT risankizumab vs PBO to week 24, then rescue, in csDMARD-IR PsA. ACR20 57% vs 34% (PBO) week 24, week 52 70%/63% ACR20. ACR 50/70 similar differences. PASI even better. @RheumNow #EULAR2022 POS1024 https://t.co/USQsMQ7oxu

Baseline molecular differences noted in PsA patients who are TNFi naive and incomplete responders. Elevated IL-22 expression may suggest increased involvement of IL-23 pathway in TNF-IR pts. @RheumNow #EULAR2022 ABST#POS0074

Vadillo et al. Clinical course in IPAF (ping @leticiakawano ) . Most frequent females in 60s. Arthritis, raynauds most common features. Most NSIP. 50% PFT deterioration 16 months. UIP, baseline fibrosis, mod/high ANA titre assoc progression @RheumNow #EULAR2022 POS1427 https://t.co/qk9zK90Wuk

Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC

Rahman et al. 2 year results on dactylitis/enthesitis from Discover-2 study guselkumab. Sustained improvements seen over time @RheumNow #EULAR2022 POS1028 https://t.co/VZhw6g4kCB

“I would not use rituximab unless I have to; use it in vasculitis/SLE nephritis, but for RA, you have other options.” – Prof. I McGinnes #EULAR2022 @rheumnow